Live Breaking News & Updates on Kempharm

Stay informed with the latest breaking news from Kempharm on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Kempharm and stay connected to the pulse of your community

KemPharm Enhances Senior Management Team

Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 -- KemPharm, Inc. ,... | January 31, 2023

Abbi-maher , Jason-rando , Daniel-gallo , Richardw-pascoe , Sanofi-genzyme , Daniel-kontoh-boateng , Company-early-access-program , Linkedin , Us-medical-affairs-at-orphazyme , Twitter , Jaguar-gene-therapy , Corium-inc

KemPharm, Inc. (NASDAQ:KMPH) CEO Travis C. Mickle Buys 3,000 Shares

KemPharm, Inc. (NASDAQ:KMPH – Get Rating) CEO Travis C. Mickle acquired 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 25th. The stock was purchased at an average price of $4.37 per share, for a total transaction of $13,110.00. Following the acquisition, the chief executive officer now directly owns 39,521 […]

United-states , Travisc-mickle , Kempharm-company-profile-get-rating , Virtu-financial , Zacks-investment-research , Renaissance-technologies , Nasdaq , Invesco-ltd , Kempharm-inc , Get-rating , Street-corp

Zacks: Analysts Expect KemPharm, Inc. (NASDAQ:KMPH) Will Announce Quarterly Sales of $3.07 Million

Equities analysts predict that KemPharm, Inc. (NASDAQ:KMPH – Get Rating) will report $3.07 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for KemPharm’s earnings. The highest sales estimate is $4.13 million and the lowest is $2.00 million. KemPharm reported sales of $12.12 million during the same […]

United-states , Canada , Blueshift-asset-management , Zacks-investment-research , Manufacturers-life-insurance-company , Nasdaq , Wells-fargo-company , Kempharm-inc , Citigroup-inc , Royal-bank , Get-rating

-$0.06 EPS Expected for KemPharm, Inc. (NASDAQ:KMPH) This Quarter

Analysts expect KemPharm, Inc. (NASDAQ:KMPH – Get Rating) to report ($0.06) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for KemPharm’s earnings, with estimates ranging from ($0.08) to ($0.03). KemPharm reported earnings per share of ($1.61) during the same quarter last year, which suggests a […]

United-states , Canada , America , Morgan-stanley , Zacks-investment-research , America-corp , Nasdaq , Invesco-ltd , Wells-fargo-company , Kempharm-inc , Royal-bank

KemPharm, Inc. (NASDAQ:KMPH) Expected to Announce Quarterly Sales of $2.24 Million

Equities analysts predict that KemPharm, Inc. (NASDAQ:KMPH – Get Rating) will announce $2.24 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for KemPharm’s earnings, with the lowest sales estimate coming in at $2.06 million and the highest estimate coming in at $2.41 million. The firm is […]

Thomson-reuter , Kempharm-company-profile-get-rating , Goldman-sachs-group-inc , Zacks-investment-research , Manufacturers-life-insurance-company , Blackrock-inc , Nasdaq , City-state-bank , Kempharm-inc , Mystic-asset-management-inc , Get-rating , Zacks-investment

KemPharm (KMPH) to Release Earnings on Wednesday

KemPharm (NASDAQ:KMPH – Get Rating) will be posting its quarterly earnings results after the market closes on Wednesday, March 30th. Analysts expect KemPharm to post earnings of ($0.08) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. KMPH stock opened at […]

Canada , Morgan-stanley , Wells-fargo-company , Squarepoint-ops , Zacks-investment-research , Kempharm-inc , Citigroup-inc , Royal-bank , Get-rating , Investment-research , Ligand-activated

KemPharm (NASDAQ:KMPH) Upgraded to "Hold" by Zacks Investment Research

Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH – Get Rating) from a sell rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports. According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product […]

United-states , Goldman-sachs-group-inc , Life-insurance-co , Zacks-investment-research , Metlife-investment-management , Renaissance-technologies , Kempharm-inc , Kovack-advisors-inc , Get-rating , Life-investment-management , Sachs-group

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 -- KemPharm, Inc. , a specialty... | March 16, 2022

Travisc-mickle , Jason-rando , Daniel-kontoh-boateng , Linkedin , Twitter , Corium-inc , Drug-administration , Exchange-commission , Youtube , Facebook , Kempharm-inc , Globenewswire-inc

KemPharm Won FDA Approval, But This Analyst Isn't Happy

KemPharm Won FDA Approval, But This Analyst Isn't Happy
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Yahoo , Fda , Kmph , Oren-livnat , Attention-deficit-hyperactivity-disorder , Cash-windfall , Kempharm , யாகூ , ஃப்ட , கி.மீ. , ஒரேன்-லிவ்னாட்

KemPharm Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent

(2)
NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid's investigational medicine Soticlestat.
Read on.
1.KemPharm Scores FDA Nod For ADHD Drug
KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FDA approval of AZSTARYS (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.

India , Japan , Bharat , Takeda-shonan , Johnson-concerta , Ovid-soticlestat , Vir-biotechnology-inc , Glaxosmithkline , Magenta-therapeutics-inc , Corium-inc , Ocugen-inc , Pfizer